30 days of each other and within the patient population receiving both tests within one day of each other. Results: Over the seven-year period, 66,066 samples were tested for HCVAB; 61,976 (93.8%) were negative, and 4,090 (6.2%) were positive. Of the 4090 HCVAB samples with positive results, 3,607 HCVAB samples underwent HCVRNA testing within 30 days, suggesting 88.2% adherence to CDC guidance for confirmation of positive HCVAB results. Of the 61,976 negative HCVAB results, 1,888 (3.0%) received confirmatory HCVRNA testing within 30 days. Among the 5,495 HCVAB samples followed up by HCVRNA testing within 30 days, there were 892 false-positive (HCVAB-positive, HCVRNA-negative) and 171 false-negative (HCVAB-negative, HCVRNApositive) results, leading to a HCVAB PPV/NPV of 75.3%/90.6%. When the analysis was limited to HCVAB/ HCVRNA test pairs that were taken within 1 day of each other (n = 1,790), the PPV/NPV improved to 78.6%/96.0%.
Conclusion:
The adherence to CDC confirmatory recommendations for patients with positive HCVAB results is high (88.2%), and a large proportion of patients with negative HCVAB results do not receive additional testing (97.0%). A small but significant proportion of patients with negative HCVAB tests will have a positive viral load within 30 days and even within one day. Although repeat testing in our study was likely to occur primarily among high-risk patients, creating the potential for bias, these findings suggest that patients with ongoing risk factors for HCV should receive follow-up testing with HCVRNA quantification. The technological revolution has changed the field of laboratory medicine with a shift from manual specimen processing to automation. Many laboratories have transitioned to robotic processing for high throughput testing in an effort to enhance workflow, improve efficiency, decrease turnaround time (TAT), and maximize resource utilization. This is beneficial for patient care and client satisfaction, and advantageous in a field of diminishing resources and skilled personnel shortages. This study analyzed the TAT for troponin testing before and after implementation of an automated laboratory at an academic medical center. Data collected included the monthly troponin TAT (reported as the time interval that 90% of samples are complete from receipt in lab to result time), and the number of troponin tests performed by the laboratory from 2015 to 2016. The medical center transitioned from Abbott ARCHITECT (i2000 SR , i1000 SR ) analyzers (North Chicago, IL) manually loaded and operated by medical technologists to the Roche cobas 8000 modular analyzer series with a modular preanalytic (MPA) system in November 2015. The MPA scans the specimen barcodes, downloads the assay requests, centrifuges the samples, aliquots them (if necessary), and triages to the appropriate analyzer using a robotic track. The TAT increased from 43.3 minutes in October 2015 (preautomation) to 113.3 minutes in November 2015 (postautomation), peaking in January 2016 at 147.5 minutes. The TAT remained above 100 minutes until a system change was implemented at the end of June 2016. The overall troponin test volume did not increase after implementation of the automated laboratory. The increase in TAT was caused by an inability to triage troponin specimens prior to being placed on the MPA and a longer than expected wait time for centrifugation once loaded on the MPA. The troponin assay and many other assays were performed using serum separator tubes, and the new system allowed multiple assays to share a tube. Therefore, no visual triage was possible for specimens with a troponin order; hence, these specimens were not preferentially loaded onto the MPA. While the troponin assay was the first test performed if other assays shared the tube, the time spent in queue was a significant delay factor. To mitigate the problem, the specimen tube for the troponin assay was changed from a serum separator tube to a designated lithium heparin tube (green top) that was only used for troponin assays. The green top was a visual signal for immediate loading onto the MPA. This helped decrease the TAT to 70.5 minutes the month after implementation with a continued downward trend to a nadir of 67.3 minutes in December 2016. The laboratory is considering the purchase of additional instrumentation to decrease TAT further. This study describes an unexpected pitfall of automation and highlights the importance of a thorough workflow assessment.
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Validation of a Multi-Wavelength Spectrophotometric Assay for Detection of Xanthochromia in Suspected Subarachnoid Hemorrhage
Paula Jenkins Colon, Geoffrey Baird;University of Washington, Seattle
Subarachnoid hemorrhage (SAH) is a catastrophic neurologic event with significant morbidity and mortality. Timely diagnosis is associated with improved outcomes. Computed tomography (CT) is the initial diagnostic procedure with sensitivity of 95% if performed within 12 hours, but sensitivity rapidly decreases and approaches 50% by one week. A more sensitive test during this interval could identify patients who would most benefit most from early intervention. Evaluation of cerebral spinal fluid (CSF) for xanthochromia is the recommended second line test and is useful beyond 12 hours, as bilirubin remains in the CSF for several weeks. Detection of xanthochromia by visual inspection is the most commonly used method in the US, but has poor sensitivity and specificity, particularly at low concentrations. Spectrophotometric analysis of CSF can detect characteristic net oxyhemoglobin absorbance (NOA) at 415 nm and net bilirubin absorbance (NBA) at 476 nm at concentrations undetected by the naked eye. Additionally, spectrophotometry can be performed on small quantities of CSF and without interferences that can confound bilirubin detection using a chemistry analyzer. Guidelines for performance and interpretation of the spectrophotometric method of bilirubin detection have been validated and adopted by the UK National External Quality Assessment Service (UK NEQAS). A spectrophotometric assay for CSF analysis existed at our tertiary care center; however, it was adapted for use on an automated chemistry analyzer with photometric capability only at predefined wavelengths. This required a lab-developed mathematical adjustment to derive the NBA, resulting in suboptimal clinical performance (although still superior to visual inspection alone). The objectives of this project were to develop and validate an assay in adherence to the UK NEQAS guidelines using Beckman Coulter DU-530 (primary instrument) and DU-730 (backup instrument) scanning spectrophotometers and to perform a method comparison with the described adapted reference assay. The clinical validation was performed on 98 clinical samples collected in a oneyear period, of which 53 (54%) were positive for blood in the subarachnoid space on chart review. The samples were scanned from 300 nm to 600 nm, and NBA and NOA calculated according to the UK NEQAS guidelines.
Results:
The new assay demonstrated significant improvement in sensitivity as compared to the reference assay (97.5% vs 72%) and improved specificity (100% vs 97%). The negative predictive value of the new assay was 96.97% vs 85% for the reference assay. The increased sensitivity of the new method decreased equivocal results by 15%. A limitation of the study is lack of correlation of sample collection time in relation to bleeding event (some samples may have been collected before or after optimal collection window). In conclusion, multi-wavelength scanning spectrophotometric CSF bilirubin assay has high sensitivity and specificity for the diagnosis of SAH and is superior to fixed wavelength spectrophotometry.
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Towards an Ideal Plasma Exchange Fluid
Christina Otterness, Charlotte Meyers, Andreia Barbieri, Anthony Colavecchia, Tina Ipe, Christopher Leveque, Eric Salazar; Houston Methodist Hospital, Houston, TX Therapeutic plasma exchange (TPE) is widely used to treat antibody-mediated conditions. TPE involves the replacement of intravascular plasma with 5% albumin, fresh frozen plasma (FFP), or a mixture of the two. Albumin is often considered the standard replacement fluid; however, TPE with albumin alone can lead to dilutional coagulopathy and, potentially, bleeding. FFP and cryoprecipitate may prevent bleeding, but their use exposes patients to risks associated with transfusion. In addition, certain patients may have religious objections to transfusion. Therefore, other means to mitigate dilutional coagulopathy should be considered. Factor concentrates, such as KCentra, containing vitamin K-dependent factors II, VII, IX, and X, protein C and protein S; RiaSTAP, a fibrinogen concentrate; Humate-P, containing factor VIII and von Willebrand factor; and Thrombate, containing antithrombin III, are increasingly being used in place of traditional blood products for the treatment of factor deficiencies. Such agents are low volume and do not impart the same risks as traditional blood products. We hypothesized that a synthetic apheresis fluid could mitigate dilutional coagulopathy resulting from TPE. Like FFP, this fluid should have a balance of procoagulant and anticoagulant factors. Using a citrated fluid consisting of a mixture of 5% albumin, KCentra, Riastap, Humate-P, and Thrombate, we tested this hypothesis in vitro on the Stago Evolution Coagulation analyzer as an initial proof of principle. Tests included the prothrombin time (PT), partial thromboplastin time (PTT), fibrinogen, thrombin time (TT), reptilase time (RT), factor II, factor V, factor VII, factor VIII, factor IX, factor X, factor XI, functional protein C, free protein S antigen, antithrombin III, and von Willebrand factor antigen levels. We performed in vitro mixing studies meant to replicate in vivo dilutional coagulopathy resulting from TPE. Normal pooled plasma alone, used as a control, showed a normal coagulation profile. Our synthetic apheresis fluid alone showed a PT >90 seconds, PTT >250 seconds, fibrinogen 158 mg/dL, and reptilase time 29.5 seconds, likely due to absence of factor V and factor XI, for which factor concentrates were not available. The sample containing 5% albumin mixed with normal pooled plasma in a 67:33 ratio meant to replicate dilutional coagulopathy from TPE showed significant coagulopathy with PT >90 seconds, PTT >250 seconds, fibrinogen 57 mg/dL, and RT >120 seconds. In the sample containing our synthetic apheresis fluid mixed with normal pooled plasma (67:33 ratio), coagulopathy was markedly improved with a PT 19.3 seconds, PTT 49.9 seconds, fibrinogen 220 mg/dL, and RT 17.8 seconds. The results provide proof of the principle that a synthetic apheresis fluid can mitigate dilutional coagulopathy. This fluid has the potential to be used as an alternative to fresh frozen plasma in TPE and in other settings where FFP or cryoprecipitate cannot be used.
